Molecular Partners Expands and Advances Robust Pipeline of DARPin(R) Therapies in Oncology and Ophthalmology
- Company Begins Development of MP0310, First DARPin® Therapy in Early-stage Immuno-oncology Portfolio - R&D Update and Webcast Today Highlights Continued Progress in Pipeline in Oncology and Ophthalmology ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / November 9, 2017 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announces continued progress...
Read more









